



ALLIANCE FOR INNOVATION
ON MATERNAL HEALTH

Perinatal Mental Health Conditions Patient Safety Bundle

Chelsea Lennox, MPH

Lead Program Manger

Alliance for Innovation on Maternal Health



Alliance for Innovation on Maternal Health

- ▶ National quality improvement initiative
- ▶ Support best practices that **make birth safer, improve maternal health outcomes,** and **save lives**
- ▶ Supported by a cooperative agreement between HRSA and ACOG





Alliance for Innovation on Maternal Health

- ▶ This program is supported by a cooperative agreement with the Health Resources and Services Administration (HRSA) of the U.S. Department of Health and Human Services (HHS) under grant number UC4MC28042, Alliance for Innovation on Maternal Health. This information or content and conclusions are those of the author and should not be construed as the official position or policy of, nor should any endorsements be inferred by HRSA, HHS or the U.S. Government.





Alliance for Innovation on Maternal Health

- ▶ AIM's primary goal is to **reduce preventable maternal mortality and severe maternal morbidity** in the United States
- ▶ AIM provides innovative training and implementation support for AIM patient safety bundles





Patient Safety Bundles





Perinatal Mental Health Conditions





Perinatal Mental Health Conditions

- ▶ **A leading cause of maternal mortality**
- ▶ Includes depression, anxiety and anxiety-related disorders like post-traumatic stress disorder and obsessive-compulsive disorder, bipolar disorder, and postpartum psychosis
- ▶ Can occur **during pregnancy or within the first year postpartum**





Perinatal Mental Health Conditions

- ▶ Perinatal mental health conditions affect upwards of **1 in 5 people**¹
- ▶ Mental health conditions, including suicide and overdose, account for approximately **10% of pregnancy-related deaths**
- ▶ MMRC's have determined **100%** of these deaths to be **preventable**²



1. Wisner 2013; Fawcett 2019; Masters 2022

2. Davis 2019, Trost 2021



Bundle Revision

- ▶ The Maternal Mental Health Patient Safety Bundle was originally released **over 7 years ago**
- ▶ In January 2022, revision to widen the scope of the bundle to:
 - ▶ Include additional health conditions
 - ▶ Incorporate respectful equitable and supportive care considerations
 - ▶ Create metrics and data collection plans to support



Equity Considerations

Respectful and
Equitable Care

- ▶ 5R Framework – Respectful, Equitable, and Supportive Care
- ▶ All AIM patient safety bundles incorporate aspects of respectful care
- ▶ Data collection plans support disaggregating data by race, ethnicity, payor, and other SDOH when possible





Bundle Revision Workgroup

Revision Workgroup

Nancy Byatt, DO, MS, MBA, FACLP
Tiffany Moore- Simas, MD, MPH, MeD
Emily Miller, MD, MPH
Camille Hoffman, MD, MSCS

Chris Raines, MSN, PMHNP-BC
John Keats, MD, CPE, FACOG
Sue Kendig, MSN, JD, WHNP
Kate Boydston

AIM Staff

Amy Ushry, RN, MPH
Christie Allen, MSN, RNC-NIC,
CPHQ, C-ONQS
Izzy Taylor, MS

David Laflamme, PhD, MPH
Hannah Kaufman, MPH
Sita Chandra, MPH



Bundle Revision External Reviewers

Representation from...



American College of Obstetricians and Gynecologists
National Healthy Start Association
2020 Mom



American College of Nurse Midwives
Association of Women's Health, Obstetric and Neonatal Nurses
National Association of Nurse Practitioner in Women's Health



Postpartum Support International
Patients with Lived Experience
State Teams/PQC's
And more...





How to Access the Bundle

- ▶ www.saferbirth.org
- ▶ Bundle
- ▶ Implementation Details
- ▶ Resource List
- ▶ IHI Change Package
- ▶ Data Collection Plan





Thank you



www.saferbirth.org



www.vimeo.com/aimprogram



aim@acog.org



ALLIANCE FOR INNOVATION
ON MATERNAL HEALTH



This program is supported by a cooperative agreement with the Health Resources and Services Administration (HRSA) of the U.S. Department of Health and Human Services (HHS) under grant number UC4MC28042, Alliance for Innovation on Maternal Health. This information or content and conclusions are those of the author and should not be construed as the official position or policy of, nor should any endorsements be inferred by HRSA, HHS or the U.S. Government.

Kentucky Newborn Screening

Lea Mott
MT (ASCP)

August 10, 2023






Kentucky Public Health
Prevent. Promote. Protect.



TEAM 
KENTUCKY[®]
CABINET FOR HEALTH
AND FAMILY SERVICES

Learning Objectives


-  Brief overview of the Newborn Screening (NBS) lab in Kentucky
-  Incidence Rates
-  Newborn Screen Reports Portal

Kentucky Department for Public Health

Mission and Vision in Action

Healthier People,
Healthier Communities.

Our mission is to improve the health and safety of people in Kentucky through prevention, promotion and protection.



The Newborn Screening Laboratory in KY

🛡️ Location: Centralized Laboratory Facility in Frankfort

🛡️ Annual Volume: Kentucky's birth rate is approximately 52,000 babies per year; ~180 specimens/day

🛡️ Days Performed: Monday-Saturday and all holidays except Thanksgiving Day, Christmas Day, and New Year's Day



Recommended Uniform Screening Panel (RUSP)

- 🛡️ RUSP: Disorders recommended by the Secretary of the Department of Health and Human Services
 - 36 Core disorders
 - 26 Secondary disorders
- 🛡️ It is recommended that every newborn be screened for all disorders on the RUSP
- 🛡️ Kentucky Newborn Screening Statute is written to align with the Recommended Uniform Screening Panel (RUSP)









<https://www.hrsa.gov/advisory-committees/heritable-disorders/rusp>

How Conditions are Added to the RUSP

- Adding a new condition to the RUSP is a multistep process: First, someone nominates the condition to the RUSP. Any person or group(s) can do this by completing a nomination package.
- The [Advisory Committee on Heritable Disorders in Newborns and Children](#) (ACHDNC) meet regularly to discuss proposals from parent advocates, organizations and experts in order to keep newborn screening up to date. In addition, the Secretary of the U.S. Department of Health and Human Services reviews the Committee's recommendations.
- Disorders on the RUSP are chosen based on evidence that supports the potential net benefit of screening, the ability of states to screen for the disorder, and the availability of effective treatments.


Steps for Adding a Condition to the RUSP

Steps for Adding a Condition to the Recommended Uniform Screening Panel (RUSP)

Step	Description
 Nominator submits a nomination package	To start the process, a team of experts and stakeholders complete a nomination package and submit it to the Committee.*
 Committee reviews the nomination package	The Committee reviews the nomination package. It considers whether the package met the requirements and addressed key questions about the condition, screening process, and treatment. If the nomination package has met the requirements, a Committee member presents a summary at a full Committee meeting.
 The Committee votes:	The Committee reviews and discusses the nomination further. If the nomination requirements are met, then the Committee will vote on whether or not to move the condition forward for more review. If the full Committee review and discussion finds that the nomination package does not meet requirements, the Committee may choose not to vote and ask the nominators to provide missing information and/or provide nominators with technical assistance on developing the nomination package.
No	If the Committee votes <i>no</i> , the condition does not move forward. The Committee will explain what else is needed, and provide technical assistance to the nominators
Yes	If the Committee votes <i>yes</i> , the condition moves forward for an evidence-based review.
 The ERG conducts an Evidence-Based Review	In an evidence-based review, an external Evidence-Based Review Group (ERG) gathers detailed data on how screening and treatment for the condition affect newborns, the population, and the public health system. The ERG prepares a final report and presents it to the Committee.
 The Committee considers the evidence	The Committee reviews the ERG report, then discusses and rates the data on three main points: screening benefits, screening feasibility, and state readiness to begin screening.
 The Committee votes:	The Committee votes on whether to recommend adding the nominated condition to the RUSP.
No	If the Committee votes <i>no</i> , it does not recommend adding the condition. The Committee will explain about what else is needed, and provide technical assistance to the nominators.
 Yes	If the Committee votes <i>yes</i> , it recommends adding the condition to the RUSP by sending a letter to the HHS Secretary.
 HHS Secretary responds	The HHS Secretary reviews the Committee recommendation and decides whether or not to add the condition to the RUSP.

*The full name of the Committee involved is the "Advisory Committee on Heritable Disorders in Newborns and Children." The Consumer Guide uses the term "Committee" to refer to this group.

Diagram of Steps for Adding a Condition to the RUSP



NBS Panel in Kentucky

- **Fatty Acid Oxidation Disorders:**
 - **Carnitine Uptake Defect (CUD)**
 - **Medium-chain Acyl-CoA Dehydrogenase Deficiency (MCADD)**
 - **Long-chain Hydroxyacyl-CoA Dehydrogenase Deficiency (LCHADD)**
 - **Trifunctional Protein Deficiency (TFP)**
 - **Very Long-chain Acyl-CoA Dehydrogenase Deficiency (VLCADD)**
 - Short-chain Acyl-CoA Dehydrogenase Deficiency (SCADD)
 - Carnitine Acylcarnitine Translocase Deficiency (CACT)
 - Carnitine Palmitoyl Transferase 1 Deficiency (CPT-1)
 - Carnitine Palmitoyl Transferase 2 Deficiency (CPT-2)
 - Ethylmalonic Encephalopathy (EE)
 - Glutaric Acidemia Type 2 (GA-2)
 - 2,4 Dienoyl-CoA Reductase Deficiency (DE RED)
- **Organic Acid Disorders:**
 - **3-Methylcrotonyl-CoA Carboxylase Deficiency (3MCC)**
 - **Glutaric Acidemia Type 1 (GA-1)**
 - **Beta-kethothiolase Deficiency (BKT)**
 - **Hydroxymethylglutaric Aciduria (HMG)**
 - **Isovaleric Acidemia (IVA)**
 - **Multiple Carboxylase Deficiency (MCD)**
 - **Methylmalonic Acidemia (MMA Cbl A form and MMA Cbl B form)**
 - **Methylmalonyl-CoA Mutase Deficiency (MUT)**
 - **Propionic Acidemia (PA)**
 - 2-Methyl-3-Hydroxybutyric Aciduria (2M3HBA)
 - 2-Methylbutyryl-CoA Dehydrogenase Deficiency (2MBDH)
 - 3-Methylglutaconic Aciduria (3MGA)
 - Methylmalonic Acidemia (MMA Cbl C form and MMA Cbl D form)
 - Malonic Acidemia (MAL)
 - Isobutyryl-CoA Dehydrogenase Deficiency (IBG)
- **Amino Acid Disorders:**
 - **Argininosuccinic Aciduria (ASA)**
 - **Citrullinemia (CIT-1)**
 - **Homocystinuria (HCY)**
 - **Maple Syrup Urine Disease (MSUD)**
 - **Phenylketonuria (PKU)**
 - **Tyrosinemia Type 1 (TYR-1)**
 - Citrullinemia Type 2 (CIT-2)
 - Hypermethioninemia (MET)
 - Hyperphenylalaninemia (H-PHE)Tyrosinemia Type 2 (TYR-2)
 - Tyrosinemia Type 3 (TYR-3)
 - Arginase Deficiency (ARG)
 - Non-Ketotic Hyperglycinemia (NKHG)
- **Endocrine Disorders:**
 - **Congenital Adrenal Hyperplasia (CAH)**
 - **Congenital Hypothyroidism (TSH and T4)**
- **Hemoglobin Disorders:**
 - **Hb S/Beta-thalassemia (HbS/Th)**
 - **Hb S/C Disease (Hb S/C)**
 - **Sickle Cell Anemia (Hb S/S)**
 - Various Hemoglobinopathies (includes Hb E)
- **Lysosomal and Peroxisomal Disorders:**
 - **Mucopolysaccharidosis (MPS-1, Hurler's Disease)**
 - **Pompe**
 - **Krabbe**
 - **X-linked adrenoleukodystrophy (X-ALD)**
- **Other Disorders:**
 - **Cystic Fibrosis (CF)**
 - **Galactosemia (GAL)**
 - **Biotinidase Deficiency (BIOT)**
 - **Severe Combined Immunodeficiency (SCID)**
 - **Spinal Muscular Atrophy (SMA)**
- **Point of Care Testing:**
 - **Critical Congenital Heart Defects**
 - **Hearing**

Core Conditions in Bold

55 disorders in total

Conditions	2016 True positive	2017 true positive	2018 true positive	2019 true positive	2020 true positive	2021 true positive	Prevalence rate	Incidence Rate
3-MCC		1	2	0	0	2	5/252,508	1/50,502
ARG		1	0	0	0	0	1/252,508	1/252,508
ASA		0	1	1	0	0	2/252,508	1/126,254
BIOT		0	0	1	0	1	2/252,508	1/126,254
BKT		1	0	0	0	0	1/252,508	1/252,508
CAH		4	1	4	1	6	16/252,508	1/15,782
Cbl A,B		0	0	0	0	0		
CF		12	27	18	15	15	87/252,508	1/2,902
CH		45	54	66	53	40	258/252,508	1/979
CIT		0	0	0	1	1	2/252,508	1/126,254
CPT-1a		0	0	0	0	1	1/252,508	1/252,508
CPT-II		0	0	0	0	0		
CUD		0	0	0	0	2	2/252,508	1/126,254
EE		0	0	0	0	0		
GA-I		1	0	2	0	0	3/252,508	1/84,169
GA-II		0	0	0	0	0		
GALt		2	2	2	0	1	7/252,508	1/36,073
Hemoglobin		15	31	12	25	16	99/252,508	1/2,577
HCY		1	0	0	0	0	1/252,508	1/252,508
IVA		0	1	1	3	1	6/252,508	1/42,085
KRABBE	1	0	0	0	0	1	2/298,084	1/126,254
LCHAD		0	0	0	0	1	3/252,508	1/84,176
MCAD		3	10	8	4	8	33/252,508	1/7,652
MCD		0	0	0	0	0		
MPS1	1	1	1	1	1	0	4/298,084	1/74,521
MSUD		0	0	0	1	0	1/252,508	1/252,508
MUT (MMA)		2	1	2	1	0	6/252,508	1/42,085
NKHG		0	1	0	0	0	1/252,508	1/252,508
OTC		0	1	0	0	0	1/252,508	1/252,508
PHE		0	0	0	0	0		
PKU		4	9	3	2	11	29/252,508	1/8,707
Pompe		3	6	1	7	2	20/298,084	1/14,904
PROP		1	2	0	1	0	4/252,508	1/63,127
SCAD		6	2	5	1	2	16/252,508	1/15,782
SCHAD		0	0	0	0	0		
SCID		1	0	1	2	3	7/252,508	1/36,073
SMA		N/A	N/A	4	4	7	15/114,154	1/7,610
TYR-I		0	1	0	0	0	1/252,508	1/252,508
TYR-II		0	0	0	0	1	1/252,508	1/252,508
VLCAD		1	1	2	0	1	5/252,508	1/50,502
X-ALD		N/A	1	2	0	1	4/174,568	1/43,642

Total True Positives


Average True Positives out of annual specimens
 2017: 52,012 initial specimens
 2018: 51,400 initial specimens
 2019: 50,520 initial specimens
 2020: 49,056 initial specimens
 2021: 49,520 initial specimens

initial specimens

137 125 121

1/400 1/400 1/400

Prevalence(2016-2021)



NBS Program in KY

Screening

- Sample collection and delivery
- Sample receipt and analysis

Follow-up

- Incomplete demographics
- Unsatisfactory samples
- Abnormal screening results

Diagnosis


- Confirmatory tests
- Clinical consultation

Clinical Management



NBS at KY DLS: Workflow



**Specimen Receipt:
Within 24-48hrs of age**



Specimen Processing



For approximately 10% of specimens, additional punches are necessary to retest abnormal results.

NBS in KY: Challenges from Lab Perspective

- 🛡️ National recommendations call for all critical results to be reported **within 5 days** and **all results to be reported within 7 days**
- 🛡️ Data from our lab:
 - 6% of specimens are delayed in transit
 - 25% of specimens are collected >30hrs (Must be 24-48hrs to meet recommendation and we prefer collection closer to 24 hours)
 - Looking at June-December 2022 we had 102 critical specimens and 24 specimens were >5 days due to collection or transit

Good quality NBS requires teamwork !



Hi Mama!



I'll be there soon...
So I hope you'll have my doctor waiting for me!

Did You Know?



Newborn Screening results are shared with your baby's doctor



If your baby needs more testing, your baby's doctor will need to contact you right away



Well-baby checkups keep your baby healthy

Now What?



Find your baby a healthcare provider before he or she is born



Make sure your birth facility knows who your baby's healthcare provider is



Give your emergency contact information to the hospital and baby's doctor

Help us educate new parents:


- Encourage them to have a pediatrician chosen prior to delivery
- Remind them to check that the pediatrician is accepting new patients
- Tell them to make sure the pediatrician takes their insurance

Newborn screening is more than just PKU

- Help us change the culture of referring to the newborn screen as “the PKU”
- Using one disorder as a shortcut for a panel that includes 54 other disorders leads to confusion

The Newborn Screen

The Kentucky Department for Public Health, Division of Laboratory Services



*Size of dot is comparative to prevalence in KY Newborn Screening testing data from 2017-2021

SMA: Spinal Muscular Atrophy, CH: Congenital Hypothyroidism,

CAH: Congenital Adrenal Hyperplasia

Learn more about conditions screened in Kentucky:

[State Newborn Screening Panel](#)




May 2023

Newborn Screen Reports Portal

My Apps

Search for Applications

 Search

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

KY DLS Portal

KSL portal provides functionality for newborn screening, microbiology and environmental branches within KSL.

Launch

NEDSS

National Electronic Disease Surveillance System. Enables KPDH reportable disease staff to report disease information to the Center for Disease Control.

Launch

Newborn Screening Reports

This application provides electronic newborn screening reports for the registered submitters and providers.

Launch

Organization Management

The Organization Management Application enables external business partner organizations to onboard and administer access to users within their organizations from a centralized management tool.

Launch

Request

The Request Application is utilized to submit application access requests and network service requests for the creation of new accounts and the provisioning/de-provisioning of entitlements.

Launch

Organization Management

Manage Organizations



Organization Search

Manage Organization Users



User Search

Home > Organizations

Org Name Search Type **Starts With**
 Org Type

Organization Name	Organization Type Name	
AGAN, MELISSA D.	Newborn Screening Reports Provider	Manage
AHMED, SYED Z.	Newborn Screening Reports Provider	Manage
AKAFUAH, RHODA A.	Newborn Screening Reports Provider	Manage
AKERS, DAVID BRADLEY	Newborn Screening Reports Provider	Manage
ALBERTSON, B. BRADLEY	Newborn Screening Reports Provider	Manage
ALEXANDRIA PRIMARY CARE	Newborn Screening Reports Provider	Manage
ALISHA RISEN	Newborn Screening Reports Provider	Manage
Alison Reid	Newborn Screening Reports Submitter	Manage
ALLEN, AMBER	Newborn Screening Reports Provider	Manage
ALLGEIER, MAURICE K.	Newborn Screening Reports Provider	Manage
ALNAHHAS, MOHAMAD H.	Newborn Screening Reports Provider	Manage
ANSERT, DOUGLAS	Newborn Screening Reports Provider	Manage
ARH REGIONAL MEDICAL CENTER HAZARD	Newborn Screening Reports Submitter	Manage
BAILEY, DEBRA R.	Newborn Screening Reports Provider	Manage
BAPTIST HEALTH CORBIN	Newborn Screening Reports Submitter	Manage
BAPTIST HEALTH DEACONESS PEDIATRICS	Newborn Screening Reports Provider	Manage
Baptist Health Hardin	Newborn Screening Reports Submitter	Manage
BAPTIST HEALTH LAGRANGE	Newborn Screening Reports Submitter	Manage
BAPTIST HEALTH LAWRENCEBURG	Newborn Screening Reports	Manage

Home > Organizations > Organization Details

[Details](#) | [Email Domains](#) | [Invite Users](#) | [Pending Invitations](#) | [Manage Users](#)

Organization Details

Organization Name:	<input type="text" value="BINGHAM, GINA L"/>	
Organization Type:	<input type="text" value="Newborn Screening Reports Provider"/>	▼
Source Unique ID:	<input type="text" value="1692"/>	

Organization Questions

Home > Organizations > BINGHAM, GINA L. > Organization Invites

Details | Email Domains | **Invite Users** | Pending Invitations | Manage Users

1. User to Invite

Search

Or

Please fill out the form below to invite a New User

* First Name:

* Last Name:

* Email Address:

Reset

2. Select Roles To Invite

Organization Admin Group(s)

Newborn Screening Reports Org Admin

Organization Roles

Role Name	App Name	
Provider	Newborn Screening Reports	Add

3. Selected Roles

Send Pending Invitations

Home > Organizations > BINGHAM, GINA L. > Organization Users

Details | Email Domains | Invite Users | Pending Invitations | **Manage Users**

Organization Users

Search Users

First Name	Last Name	Email Address	Remove User From Organization	User Details
Elizabeth	Boggs	elizabetha.boggs@ky.gov	Remove	Manage
Heather	Smith	HeatherA.Smith@ky.gov	Remove	Manage

Welcome to Kentucky Division of Laboratory Services - Newborn Screening Reports

Report Search - Help Desk

Mother Last Name

Ex. Allen

Mother First Name

Ex. Marry

Baby Last Name

Ex. Allen

Baby First Name

Ex. Kristen

Baby Date of Birth

MM/DD/YYYY

Submitter Name

-Please Select-

Accession No

Ex. 1234567891

KyChildLabNo

Ex. 123456

Physician Name

Ex. Philip

Mother SSN

Ex. 111111111

Submit

Cancel

NBS Reports

Search:

		Accession No	Mother Last Name	Mother First Name	Baby Last Name	Baby First Name	Baby DOB	Submitter Name	Physician Name
Screening under process	Card	1234567890	TEST	TEST	TEST	BABY	05/27/2016	HOSPITAL	TEST,PHYSICIAN

Showing 1 to 1 of 1 entries

Previous Next

Report Search - Help Desk

Mother Last Name

Ex. Allen

Mother First Name

Ex. Marry

Baby Last Name

Ex. Allen

Baby First Name

Ex. Kristen

Baby Date of Birth

MM/DD/YYYY

Submitter Name

-Please Select-

Accession No

1234567890

KyChildLabNo

Ex. 123456

Physician Name

Ex. Philip

Mother SSN

Ex. 111111111

Submit

Cancel

NBS Reports

Search:

		Accession No	Mother Last Name	Mother First Name	Baby Last Name	Baby First Name	Baby DOB	Submitter Name	Physician Name
Report	Card	1234567890	TEST	TEST	TEST	BABY	05/27/2016	HOSPITAL	TEST,PHYSICIAN

Showing 1 to 1 of 1 entries

Previous Next

Report Search - Help Desk

Mother Last Name

Mother First Name

Baby Last Name

Baby First Name

Baby Date of Birth

Submitter Name

Accession No

KyChildLabNo

Physician Name

Mother SSN

Newborn Screening Tests

Mother's Name (L,F): TEST, TEST
 Mother's Address: 100 MAIN ST
 City, State, Zip: CITY, KY 40004 502 XXXX
 Mother's Phone: XXXX
 Mother's SSN: XXX-XX-XXXXX
 Submitter: HOSPITAL
 Submitter's Address: 100 N AVENUE
 City, State, Zip: CITY, KY 42701
 Date Reported: Date Collected: 5/29/16
 Baby's Name (L,F): TEST, BABY
 Date of Birth: 5/27/16 12:54 pm
 Baby's Sex: F Baby's Weight: 3,515 g
 Gestation Age: Greater than or equal to 37 Weeks
 Physician: TEST, PHYSICIAN
 Physician's Phone: 1234567890
 Physician's Address: 100 MAIN ST
 City, State, Zip: CITY, KY 42701
 Test Type: Initial

Disorder:	Analyte:	Results:	Normal Reference Range:	Comments:
Biotinidase Deficiency	Biotinidase	[Full Enzyme Activity Detected]	Full Enzyme Activity	
Congenital Adrenal Hyperplasia	17-OHP	[Normal]	Within Normal Limits*	
Congenital Hypothyroidism	T4,TSH	[Normal]	Within Normal Limits**	
Cystic Fibrosis (CF)	IRT	[Normal]	Within Normal Limits***	
Galactosemia	Galactose-1-Phosphate Uridyltransferase	[Full Enzyme Activity Detected]	Full Enzyme Activity	
Hemoglobinopathies	Hemoglobin	[Not Requested]	Not Tested	
Fatty Acid Oxidation Disorders	Fatty Acids	[Not Requested]	Not Tested	
Amino Acid Disorders	Amino Acids	[Not Requested]	Not Tested	
Organic Acid Disorders	Organic Acids	[Not Requested]	Not Tested	
SCID	TREC	[Within Normal Limits]	TREC Within Normal Limits	
Lysosomal Storage Disorders	Lysosomal Enzymes	[Full Enzyme Activity Detected]	Full Enzyme Activity****	

*Congenital Adrenal Hyperplasia-17OHP normal weight-based limits for all initial specimens and repeat specimens on infants less than one week old: <1500g: <70 ng/mL; 1500g-2500g: <40 ng/mL; >2500g: <25 ng/mL. Normal limit for repeat specimens on infants greater than one week old of any weight is <25 ng/mL. Treatment of the mother or the child with steroids may result in false negative results.

**T4 - Normal for specimens from infants < 4 weeks of age is 5-27 µg/dL. Normal T4 for specimens from infants > or = 4 weeks of age is 5-19 µg/dL. Normal TSH is <20 µU/mL. TSH values below 2.91, the lower limit of linearity for this method, will be reported as <2.91. Rare hypothalamic and pituitary disorders may be causes of fetal hypothyroidism with low TSH and low T4. Neonates born to women with Graves' disease may have fetal hypothyroidism with low TSH and normal elevated T4. Recommend clinical correlation and follow up as indicated.

***IRT - Normal for initial specimens from infants < 4 weeks of age is <5 ng/mL. IRT - Normal for initial specimens from infants > or = 4 weeks of age is <50 ng/mL. IRT - Normal for repeat specimens (regardless of age) is <50 ng/mL. Meconium films may result in false negative results.

****Enzyme activities of galactose-1-phosphate, acid alpha-glucosidase, and alpha-L-iduronidase. Testing performed at Mayo Medical Laboratories, 3050 Superior Drive NW, Rochester, MN 55901.

-Specimen source: dried blood spots.

-This report contains patient information that must be protected in accordance with the Health Insurance Portability and Accountability Act.

-Analyte Specific Reagent: The Severe Combined Immunodeficiency assay was developed and the performance characteristics determined by Kentucky Division of Laboratory Services. It has not been cleared or approved by the U.S. Food And Drug Administration.

Jeremy Hart MD, FCAP
 Jeremy Hart MD, FCAP
 Director - (502) 564-4446

Vaneet Arora MD MPH
 Vaneet Arora MD, MPH
 Associate Director - (502) 564-4446

**TEST HOSPITAL ATTENTION:
 NURSERY
 100 N AVENUE
 CITY, KY 42701**

TESTS CONDUCTED:

Enzyme Immunoassay: Congenital Adrenal Hyperplasia (CAH), Congenital Hypothyroidism (CH), Cystic Fibrosis (CF), Galactosemia (GALT), Biotinidase (BIO)

High Performance Liquid Chromatography (HPLC): Hemoglobinopathies

Tandem Mass Spectrometry (MS/MS):

Fatty Acid Oxidation Disorders: Medium-chain acyl-CoA dehydrogenase deficiency (MCADD), Very long-chain acyl-CoA dehydrogenase deficiency (VLCADD), Long-chain 3-hydroxyacyl-CoA dehydrogenase deficiency (LCHADD), Trifunctional protein deficiency (TFP), Carnitine uptake defect (CUD), Carnitine acylcarnitine translocase deficiency (CACT), Carnitine palmitoyl transferase I deficiency (CPT-I), Carnitine palmitoyl transferase II deficiency (CPT-II), Glutaric acidemia type II (GA-II), Short-chain acyl-CoA dehydrogenase deficiency (SCADD)

Amino Acid Disorders: Argininosuccinic acidemia (ASA), Citrullinemia Type I (CIT-I), Tyrosinemia Type I (TYR-I), Maple syrup urine disease (MSUD), Homocystinuria (HCY), Phenylketonuria (PKU), Argininemia (arginase deficiency) (ARG), Citrullinemia Type II (CIT-II), Hyperphenylalaninemia (H-PHE), Hypermethioninemia (MET), Tyrosinemia Type II (TYR-II), Tyrosinemia Type III (TYR-III), Nonketotic Hyperglycinemia (NKHG)

Organic Acid Disorders: Beta-ketothiolase deficiency (BKT), Isovaleric acidemia (IVA), Glutaric acidemia Type I (GA-I), 3-Hydroxy-3-methylglutaric aciduria (HMG), Multiple carboxylase deficiency (MCD), 3-Methylcrotonyl-CoA carboxylase deficiency (3MCC), Methylmalonic acidemia (MMA Cbl A, B, C, D), Methylmalonyl-CoA mutase deficiency (MUT), Propionic acidemia (PA), 2-Methyl-3-Hydroxybutyric aciduria (2M3HBA), 3-Methylglutaconic aciduria (3MGA), Isobutyryl-CoA dehydrogenase deficiency (IBD), Malonic acidemia (MAL), Ethylmalonic encephalopathy (EE), 2-Methylbutyryl-CoA dehydrogenase deficiency (2MBDH)

Real-Time Polymerase Chain Reaction (PCR): T-Cell Receptor Excision Circles (TREC) for Severe Combined Immunodeficiency

Flow Injection Analysis-Tandem Mass Spectrometry:

Lysosomal Storage Disorders: Krabbe Disease, Pompe Disease, Mucopolysaccharidosis Type I (MPS I) [Testing performed at Mayo Medical Laboratories in Rochester, MN]

The laboratory values in this report represent screening test results and are intended to identify infants at risk for selected disorders and in need of more definitive testing. The above results should be correlated clinically with consideration of age at the time of collection, nutrition, birth weight, prematurity, health status, and treatments. It is very important for physicians to be aware that a negative screening result does not indicate with certainty the absence of the above listed disorders. The physician should be alert to the clinical symptoms of these conditions, so that diagnosis and treatment can take place as early as possible in infants who are not identified through the newborn screening program.

NEW EXPANDED NEWBORN SCREENING PROGRAM
Cabinet for Health and Family Services - Laboratory Services
100 Sower Blvd, Suite 204 Frankfort, KY 40601
Tel. # (502)564-4446 Ext. 4433 Fax # (502)564-2905 or 2413



864357

MOTHER'S INFORMATION

CHILD'S INFORMATION

TEST		TEST	
First Name	XXX-XX-XXX	Last Name	XXX
Social Security Number		County of Residence	
TEST			
Street Address (P.O. Box)	CITY	KY	4004
	City	State	Zip Code
XXXXXX	XXXXXX		XXXXXXX
Mother's Phone Number	Alternate Phone Number	Mother's email address	

BABY		TEST	
First Name		Last Name	
DOB: 5/27/16	TIME: 12:54PM	(Military) <input checked="" type="checkbox"/> Male	XXXX
		<input type="checkbox"/> Female	Race
37 WEEKS	<input checked="" type="checkbox"/> Single Birth	3515G	
Gestational Age:	<input type="checkbox"/> Multiple Birth	(A,B,C etc.)	Birth Weight
<input type="checkbox"/> Antibiotics	<input type="checkbox"/> Meconium ileus	<input type="checkbox"/> Transfused - Last Date:	Time:
<input type="checkbox"/> TPN	<input checked="" type="checkbox"/> Breast	<input checked="" type="checkbox"/> Bottle	Date of First Feeding: XXXXX
XXXXXX			
Medical Record Number	<input type="checkbox"/> Baby still in NICU	<input type="checkbox"/> Home Birth	

SUBMITTER INFORMATION

SPECIMEN COLLECTION

Submitter's ID#	XXXXXXXX	Phone#	XXXXXXXX
Facility Name	HOSPITAL		
Address	100 N AVENUE, CITY, KY, 42701		

Collection Facility:	<input checked="" type="checkbox"/> Hospital	<input type="checkbox"/> Dr.'s Office	<input type="checkbox"/> Midwife	<input type="checkbox"/> Health Dept.	<input type="checkbox"/> Other
Specimen type:	<input checked="" type="checkbox"/> Initial Screen	<input type="checkbox"/> Repeat Screen			
Was Previous Specimen Unsatisfactory or Sub-optimal?	<input type="checkbox"/> Yes <input checked="" type="checkbox"/> No				
Date Collected:	05/29/16	Time:		(Military)	

PHYSICIAN INFORMATION

COMMENTS: XXXXXXXX Collector: XXXXXXXX

License#:	XXXXXX	Phone #:	XXXXXX		
Name:	TEST, PHYSICIAN				
Street Address (P.O.)	100 MAIN ST				
City:	CITY	State:	KY	Zip Code:	42701

AFFIX MEDICAL LABEL(S) HERE

INFORMATION MUST BE PROTECTED ACCORDING TO HIPAA GUIDELINES

GOOD THROUGH 2026-08-31

LOT 7221321W201



Welcome to Kentucky Di

Newborn Screening Reports

- How to Collect Blood Spot Specimen
- Unsatisfactory Examples
- Baby Poster
- Not Just PKU Beaker
- Newborn Screening Tests Conducted
- Newborn Screening Program Statement
- KRS 214.155
- Sec 902 KAR 4 030
- Kentucky Newborn Screening Incidence Rates
- Presentation for Intern
- Blood Card Punches
- Picture Incident Graph
- Frequently asked NBS Questions**
- Brochures ▾
- Videos ▾

Thank You!

Questions & Comments

Lea Mott,
Newborn Screening
Lea.mott@ky.gov